Please assess the completion status of the following clinical trial:

Trial Title: Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically confirmed diagnosis of recurrent or refractory high-grade glioma (anaplastic astrocytoma, WHO grade III; or glioblastoma, WHO grade IV)~* Supratentorial localization~* No more than two chemotherapy regimens including radiochemotherapy since primary diagnosis~* Eligible for either TMZ or PCV treatment~* Recovery from acute toxicity caused by any previous therapy~* Adequate organ functions~* KPS at least 70%~Exclusion Criteria:~* Tumor surgery within 2 weeks prior to study entry~* Radiation therapy within 8 weeks prior to study entry~* Chemotherapy within 4 weeks prior to study entry (nitrosureas: 6 weeks)~* No more than 3 mg/day dexamethasone (or equivalent) at baseline~* Prior TGF-beta targeted therapy or tumor vaccination~* Baseline MRI shows mass effect~* Known active infection with HIV, HBV, or HCV; acute viral, bacterial, or fungal infection~* Significant psychiatric disorders/legal incapacity or a limited legal capacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AP 12009 10 µM (Type: EXPERIMENTAL): None
- AP 12009 80 µM (Type: EXPERIMENTAL): None
- Chemotherapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).